Clinical Trial

A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) of JNJ-69086420 in Part 1 (Dose Escalation), to determine safety and preliminary signs of clinical activity at the RP2D(s) in Part 2 (Dose Expansion), to determine safety of JNJ-69086420 at the RP2D(s) as a combination therapy in Part 3 (combination therapy) and to determine safety of JNJ-69086420 at the RP2D(s) in participants with metastatic hormone-sensitive prostate cancer (mHSPC) in Part 4.
Trial Details
NCT Number NCT04644770
Lead Sponsor Janssen Research & Development, LLC
Conditions Prostatic Neoplasms, Adenocarcinoma
Enrollment 144 participants
Start Date 2020-11-12
Primary Completion 2026-12-08 (estimated)
Study Completion 2026-12-08 (estimated)
Updated on ClinicalTrials.gov 2026-06-05